β-Cyclodextrin-Based Nanosponges Functionalized with Drugs and Gold Nanoparticles.
2-amino-4-(4-chlorophenyl)thiazole (AT)
carrier of therapeutic agents
gold nanoparticles
phenylethylamine
β-cyclodextrin-based nanosponge
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
08 Apr 2021
08 Apr 2021
Historique:
received:
17
02
2021
revised:
01
04
2021
accepted:
04
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Drugs are widely used as therapeutic agents; however, they may present some limitations. To overcome some of the therapeutic disadvantages of drugs, the use of β-cyclodextrin-based nanosponges (βCDNS) constitutes a promising strategy. βCDNS are matrices that contain multiple hydrophobic cavities, increasing the loading capacity, association, and stability of the included drugs. On the other hand, gold nanoparticles (AuNPs) are also used as therapeutic and diagnostic agents due to their unique properties and high chemical reactivity. In this work, we developed a new nanomaterial based on βCDNS and two therapeutic agents, drugs and AuNPs. First, the drugs phenylethylamine (PhEA) and 2-amino-4-(4-chlorophenyl)-thiazole (AT) were loaded on βCDNS. Later, the βCDNS-drug supramolecular complexes were functionalized with AuNPs, forming the βCDNS-PhEA-AuNP and βCDNS-AT-AuNP systems. The success of the formation of βCDNS and the loading of PhEA, AT, and AuNPs was demonstrated using different characterization techniques. The loading capacities of PhEA and AT in βCDNS were 90% and 150%, respectively, which is eight times higher than that with native βCD. The functional groups SH and NH
Identifiants
pubmed: 33917938
pii: pharmaceutics13040513
doi: 10.3390/pharmaceutics13040513
pmc: PMC8068376
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : ANID doctoral scholarship
ID : 21180548
Organisme : ANID-FONDECYT for postdoctoral research grant
ID : 3180706
Organisme : ANID-FONDAP
ID : 15130011
Références
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Mater Sci Eng C Mater Biol Appl. 2021 Feb;121:111785
pubmed: 33579441
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jul;8(4):579-601
pubmed: 26800431
Nanomedicine (Lond). 2014 Sep;9(13):2023-39
pubmed: 25343351
J Control Release. 2010 Nov 20;148(1):122-127
pubmed: 20547192
Int J Pharm. 2017 Oct 15;531(2):470-479
pubmed: 28645630
Chem Rev. 2015 Aug 12;115(15):7794-839
pubmed: 25415447
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jul;9(4):
pubmed: 28160445
J Biomed Nanotechnol. 2016 Jan;12(1):114-27
pubmed: 27301177
Chem Rev. 1997 Aug 5;97(5):1325-1358
pubmed: 11851454
Nanomedicine. 2017 Oct;13(7):2341-2350
pubmed: 28673851
J Med Chem. 2006 Nov 16;49(23):6819-32
pubmed: 17154512
Acc Chem Res. 2008 Dec;41(12):1721-30
pubmed: 18712884
J Mater Chem B. 2018 Aug 21;6(31):5091-5099
pubmed: 32254537
Chemistry. 2015 Jan 7;21(2):829-35
pubmed: 25376633
J Am Chem Soc. 2016 Feb 24;138(7):2292-301
pubmed: 26812983
Int J Nanomedicine. 2017 Aug 22;12:6131-6152
pubmed: 28883725
Small. 2009 Jul;5(13):1553-61
pubmed: 19326357
Expert Opin Drug Deliv. 2014 Jan;11(1):111-20
pubmed: 24298891
Talanta. 2018 Jul 1;184:537-556
pubmed: 29674080
Carbohydr Polym. 2020 Apr 1;233:115865
pubmed: 32059912
Nanoscale. 2012 Mar 21;4(6):1871-80
pubmed: 22076024
Br J Radiol. 2012 Feb;85(1010):101-13
pubmed: 22010024
Webmedcentral. 2013 Sep 30;4(9):
pubmed: 24482732
Biosens Bioelectron. 2015 Jun 15;68:429-436
pubmed: 25618374
Carbohydr Polym. 2020 Mar 1;231:115763
pubmed: 31888848
Carbohydr Polym. 2017 Oct 1;173:37-49
pubmed: 28732878
ACS Appl Mater Interfaces. 2015 Jul 22;7(28):15177-88
pubmed: 26091143
Nano Lett. 2010 Sep 8;10(9):3223-30
pubmed: 20726522
Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8
pubmed: 11229762
Anticancer Drugs. 2011 Jul;22(6):543-55
pubmed: 21471809
J Mater Chem B. 2017 Jan 7;5(1):36-52
pubmed: 32263433
PLoS One. 2017 Oct 11;12(10):e0185652
pubmed: 29020065
Expert Opin Drug Deliv. 2017 Mar;14(3):331-340
pubmed: 27449474
Int J Mol Sci. 2013 Feb 07;14(2):3671-82
pubmed: 23434664
Adv Enzyme Regul. 2001;41:189-207
pubmed: 11384745
Colloids Surf B Biointerfaces. 2007 Jul 1;58(1):3-7
pubmed: 16997536
Int J Pharm. 2013 Aug 30;453(1):167-80
pubmed: 22771733
Eur J Pharm Biopharm. 2010 Feb;74(2):193-201
pubmed: 19900544
Mol Pharm. 2007 Mar-Apr;4(2):189-98
pubmed: 17256872
Nanomedicine (Lond). 2013 Oct;8(10):1601-9
pubmed: 23265347
Eur J Med Chem. 2003 Mar;38(3):313-8
pubmed: 12667698
Carbohydr Polym. 2017 Dec 1;177:22-31
pubmed: 28962762
Chem Rev. 2012 May 9;112(5):2739-79
pubmed: 22295941
Pharmaceutics. 2021 Feb 15;13(2):
pubmed: 33671975
J Pharm Sci. 2003 May;92(5):927-32
pubmed: 12712411
Saudi Pharm J. 2020 Mar;28(3):349-361
pubmed: 32194337
Br J Sports Med. 2001 Oct;35(5):342-3
pubmed: 11579070
Curr Drug Deliv. 2011 Mar;8(2):194-202
pubmed: 21235471
Nanomaterials (Basel). 2018 Nov 28;8(12):
pubmed: 30486514
Angew Chem Int Ed Engl. 2013 Jan 21;52(4):1148-51
pubmed: 23233455
Adv Drug Deliv Rev. 2013 Aug;65(9):1215-33
pubmed: 23673149
Carbohydr Polym. 2018 Jun 15;190:23-30
pubmed: 29628242